Peptide News Digest

Petrelintide Phase 3 Endorsement, STAT Op-Ed on Peptide Risks, Rein LTI-03 IPF Update, FDA Real-Time Trial Monitoring

Zealand/Roche advance petrelintide to Phase 3; STAT warns RFK peptide push could unleash risky drugs; Rein LTI-03 IPF Phase 2 update; FDA pilots real-time trial monitoring.

10 stories · Covering clinical-trials, regulatory, industry, research

Editor's Note

Today's sharpest corporate signal is Zealand Pharma and Roche formally endorsing petrelintide for Phase 3 — a direct challenger to Novo's CagriSema; on the same day, Novo Nordisk previewed 52 ECO 2026 abstracts on CagriSema REDEFINE 1 body composition, cardiovascular risk, and Wegovy variants, setting up a consequential amylin/GLP-1 data showdown in Istanbul in May. STAT News published a counter-argument to RFK Jr.'s peptide-push narrative, arguing that restoring compounding access to inadequately-tested compounds poses immunogenicity and impurity risks the 2023 Category 2 designations were meant to guard against. On the clinical pipeline side, Rein Therapeutics' LTI-03 Phase 2 RENEW trial in idiopathic pulmonary fibrosis enrolled 8 patients — one of the few peptide candidates in the IPF space — while the FDA announced it has completed first tests of a real-time clinical trial data system, shifting from batch reporting to a live stream. The day's research output spans five distinct peptide modalities: a PLOS Computational Biology model for B-cell epitope prediction, a Scientific Reports peptide enabling inhaled pulmonary cAMP modulation, final AMPLIFY-201 results for the KRAS amphiphile vaccine, 20-year melanoma vaccine survival data, and Eli Lilly's $7B Kelonia CAR-T acquisition underscoring how pharma is now betting beyond GLP-1 across the full therapeutic peptide spectrum.

Correction (October 5, 2026): The Mel39 melanoma vaccine item originally attributed the 65% 10-year and 49% 20-year overall survival rates to the 12-peptide arm and said the data showed that antigen breadth drives durability. Those rates cover both vaccine arms combined, the difference between arms was not statistically significant, and the authors concluded that more peptides did not significantly improve clinical efficacy.

Clinical Trials

Zealand Pharma and Roche Formally Endorse Petrelintide for Phase 3 Trials in Chronic Weight Management

Zealand Pharma announced April 29 that it and partner Roche have formally endorsed advancing petrelintide — a long-acting amylin analog suitable for once-weekly subcutaneous administration — into Phase 3 trials for chronic weight management, with initiation planned for H2 2026. The Phase 3 program will evaluate petrelintide as monotherapy and in combination with Roche's GLP-1/GIP receptor dual agonist enicepatide (CT-388). The decision follows positive Phase 2 ZUPREME-1 data showing up to 10.7% weight loss with placebo-like tolerability; petrelintide is now positioned as the lead non-GLP-1 obesity asset behind only Novo's CagriSema.

#zealand-pharma #roche #petrelintide #amylin #phase-3 #weight-management
Regulatory

STAT First Opinion: "RFK Jr.'s Peptide Push Could Unleash Risky Drugs" Lands as Pre-PCAC Counter-Argument

STAT News published an April 29 First Opinion piece arguing that the FDA's pending peptide reclassifications — driven by HHS Secretary RFK Jr.'s public enthusiasm for compounds like BPC-157 and GHK-Cu — risk reopening access to inadequately-tested compounds. The op-ed highlights specific safety concerns flagged in the FDA's original 2023 Category 2 designations: immunogenicity, impurities, and the absence of meaningful human clinical data. The piece is positioned as scientific-community pushback ahead of the July 23-24 PCAC meeting that will rule on seven peptides.

#stat-news #rfk-jr #fda-pcac #peptide-safety #bpc-157 #compounding
Clinical Trials

Rein Therapeutics LTI-03 Phase 2 RENEW Trial Update: 8 Patients Enrolled in Idiopathic Pulmonary Fibrosis Study

Rein Therapeutics announced April 29 a clinical update for its Phase 2 RENEW trial of LTI-03 — a peptide therapeutic for idiopathic pulmonary fibrosis (IPF). 8 patients have been enrolled to date, with 2 additional patients expected to be enrolled this week. Enrollment began March 2026 and continues steadily. LTI-03 is one of the few peptide candidates in the IPF space, where current standards of care (pirfenidone, nintedanib) have meaningful tolerability limits. The peptide-based approach is mechanistically distinct, targeting Caveolin-1-related fibrotic pathways.

#rein-therapeutics #lti-03 #renew-trial #idiopathic-pulmonary-fibrosis #phase-2 #caveolin-1
Regulatory

FDA Pilots Real-Time Clinical Trial Patient Monitoring System for Faster Drug Review

The FDA announced April 28 that it has completed first tests of a real-time data system that allows agency scientists to view safety and effectiveness data from clinical trial patients as it is collected — shifting from the traditional stop-and-go batch reporting model to a continuous live data stream. The pilot affects all therapeutic categories including peptide drugs, with implications for trial timelines, regulatory review speed, and adverse-event detection. Industry observers see the move as part of broader systemic agency change under the new HHS leadership.

#fda #clinical-trial-monitoring #real-time-data #drug-review #regulatory-modernization
Industry

Eli Lilly Closes $7B Kelonia Therapeutics Acquisition for In Vivo CAR-T Cancer Cell Therapy Platform

Eli Lilly's acquisition of Kelonia Therapeutics — announced April 20 with $3.25 billion upfront and up to $7 billion total including milestones — illustrates the company's broader pivot beyond GLP-1 weight-loss drugs. Kelonia develops in vivo CAR-T technology that reprograms patients' T-cells inside the body, eliminating the ex vivo cell-engineering step required by current CAR-T therapies. The deal joins Lilly's recent Centessa Pharmaceuticals (sleep) and Orna Therapeutics (cell therapy) acquisitions as part of a multi-vertical pipeline diversification. Transaction expected to close H2 2026.

#eli-lilly #kelonia #in-vivo-car-t #cell-therapy #cancer #pipeline-diversification
Research

PLOS Computational Biology: MsgaBpred Model Improves B-Cell Epitope Prediction for Vaccine and Diagnostic Peptide Design

A PLOS Computational Biology paper published April 28 introduced MsgaBpred, a multi-scale graph attention model for predicting B-cell epitopes — short peptide sequences recognized by antibodies. The model achieved high accuracy on cross-species benchmarks and is directly relevant for peptide vaccine antigen design, diagnostic peptide development, and antibody-target discovery. The work joins the broader 2026 wave of AI-driven peptide tooling, complementing the Nature Communications DDA-BERT and CycloSEL papers from earlier in the month.

#msga-bpred #b-cell-epitope #vaccine-design #ai-peptide-design #plos-computational-biology
Research

Scientific Reports: Peptide Targeting PI3Kγ A-Kinase Anchoring Function Shows Inhaled Delivery Properties for Pulmonary cAMP Modulation

A 2026 Scientific Reports paper characterized the biophysical and aerodynamic properties of PI3Kγ MP (KIT2014), a non-natural peptide that disrupts the AKAP-PKA interaction by mimicking PI3Kγ's A-kinase anchoring function. The peptide adopts a partially structured conformation essential for PKA binding, assembles into dynamic nanoparticles compatible with epithelial and mucus penetration, and retains full biological activity in protease-rich environments — enhancing β₂-adrenergic receptor-driven cAMP signaling to promote airway relaxation, mucus clearance, and reduced inflammation in pulmonary cells. The work builds the case for peptide-based AKAP disruptors as inhaled therapeutics for chronic inflammatory airway diseases including asthma and COPD.

#pi3k-gamma #akap #pulmonary-camp #inhaled-peptides #airway-inflammation #scientific-reports
Clinical Trials

Nature Medicine: AMPLIFY-201 Final Results — ELI-002 2P KRAS Amphiphile Vaccine Delivers Durable Relapse-Free Survival in Pancreatic and Colorectal Cancer

Final phase 1 AMPLIFY-201 results published in Nature Medicine report that ELI-002 2P — a lymph node-targeted vaccine combining amphiphile-modified mutant KRAS G12D/G12R peptides with CpG-7909 adjuvant — produced durable responses in 25 patients with minimal residual mKRAS disease (20 pancreatic, 5 colorectal). At 19.7 months median follow-up, robust T-cell responders achieved median relapse-free survival not reached vs. 3.02 months in non-responders (HR 0.12, p=0.0002); 71% of evaluable patients generated both CD4+ and CD8+ T cells, and antigen spreading was observed in 67%. Phase 2 enrollment of the next-generation 7-peptide formulation ELI-002 7P is complete, with results expected in 2026.

#eli-002 #kras-vaccine #amplify-201 #pancreatic-cancer #amphiphile-peptide #nature-medicine
Research

International Journal of Cancer: 20-Year Follow-Up of the Mel39 Multipeptide Melanoma Vaccine Trial Reports 49% Overall Survival Across Both Arms

A post-hoc analysis in the International Journal of Cancer followed 51 patients from the Mel39 randomized Phase 2 trial, in which people with resected stage IIB-IV melanoma received a vaccine of 4 or 12 melanoma peptides. At a median follow-up of 16.1 years (21.2 years for living participants), overall survival across both arms was 65% at 10 years and 49% at 20 years. Survival favored the 12-peptide vaccine (hazard ratio 0.64, 95% CI 0.29-1.40), but the difference was not statistically significant (p = 0.26), and the authors concluded that adding more peptides did not significantly improve clinical efficacy; women had significantly better recurrence-free survival than men after either vaccine.

#melanoma #multipeptide-vaccine #long-term-survival #cancer-vaccine #mel39-trial #adjuvant-immunotherapy
Industry

Novo Nordisk Previews 52 ECO 2026 Abstracts on CagriSema, Higher-Dose Wegovy, and Women's Obesity Data Ahead of Istanbul Congress

Novo Nordisk announced April 28 that it will present 52 abstracts at the European Congress on Obesity (ECO 2026, Istanbul, May 12–15), including new data from the REDEFINE 1 trial of CagriSema (cagrilintide 2.4 mg/semaglutide 2.4 mg): body composition and muscle strength, achievement of BMI/waist-to-height ratio targets, and cardiovascular risk reduction. Additional presentations will cover higher-dose Wegovy (semaglutide 7.2 mg), the Wegovy pill (oral semaglutide 25 mg) from OASIS 4 and ORION trials, and obesity treatment outcomes in women. The disclosure sets up a significant amylin/GLP-1 combination data event exactly as Zealand and Roche's amylin-only petrelintide moves into Phase 3.

#novo-nordisk #cagrisema #cagrilintide #wegovy #eco-2026 #redefine-1 #amylin

Related Guides